Bavarian unconcerned by Moderna RSV advance: ”It's completely as expected"

Bavarian Nordic is not worried by the news that Moderna has announced a phase III trial of its RSV vaccine, positioning the US-based firm ahead of the Danish one in the race to reach the potentially lucrative RSV market. ”Old news,” says VP of Investor Relations & Communications Rolf Sass Sørensen.
Photo: Philip Davali/Ekstra Bladet, Philip Davali
Photo: Philip Davali/Ekstra Bladet, Philip Davali
by ALBERT RØNNING-ANDERSSON, translated by daniel pedersen

Another competitor is now breathing down Bavarian Nordic’s neck, as Moderna announced its next step after a successful phase II with its vaccine against respiratory syncytial virus (RSV) on Tuesday.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading